Even if you acknowledge the limitations of the data (insulin as a comparison, we cant review the full paper yet), a finding like fewer deaths is always a positive sign, and its an endpoint thats impossible to achieve with a placebo effect or manipulate with selective criteria
Changes in Mood Some people notice feeling more irritable, anxious, or emotional
Conversely, weight gain occurs when you consume more calories than you burn
6 Combining this with regular aerobic activity like walking provides the best overall benefit
Resmetirom, which was also approved in August 2025 by the European Medicines Agency (EMA), is indicated for the treatment of adults with noncirrhotic MASH with moderate to advanced fibrosis and has been administered to over 23 000 patients in the USA ( On August 15th, 2025, the FDA granted an accelerated and conditional approval of the subcutaneous glucagonlike peptide (GLP1) receptor agonist (GLP1RA) semaglutide 2.4 mg/week for the treatment of MASH with moderate to advanced fibrosis (Stage F2F3) [7]